Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 2 Surgical Wound Infection 1 Sepsis 1 Neoplasms, Plasma Cell 1 Multiple Myeloma 1 Multiple Endocrine Neoplasia Type 1 1 Melanoma 1 Lymphoma 1 Leukemia, Myeloid, Acute 1 Leukemia 1 Hematologic Neoplasms 1 Glioblastoma 1 Febrile Neutropenia 1 Exanthema 1 Discitis 1 Diarrhea 1 Colonic Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1

Interventions

Ipilimumab 114 pembrolizumab 95 Nivolumab 91 aldesleukin 86 Interleukin-2 57 Cyclophosphamide 54 Dacarbazine 52 Vemurafenib 39 trametinib 37 Temozolomide 37 incomplete Freund's adjuvant 35 fludarabine phosphate 35 sargramostim 32 dabrafenib 32 fludarabine 26 Bevacizumab 26 Paclitaxel 22 MART-1 Antigen 21 Granulocyte-Macrophage Colony-Stimulating Factor 21 montanide ISA 51 20 Interferon-alpha 20 Cisplatin 20 Carboplatin 19 Sorafenib 18 Introns 17 Biopsy 17 cobimetinib 16 Radiosurgery 16 atezolizumab 15 Radiotherapy 15

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Melanoma × Anti-Bacterial Agents × Clear all

NCT03817125 2024-06-06

MCGRAW

Parker Institute for Cancer Immunotherapy

Phase 1 Completed

14 enrolled 22 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡